retinal imaging with low-cost OCT device for Optical Coherence Tomography of Retina

Phase-Based Progress Estimates
Duke University Medical Center, Durham, NC
Optical Coherence Tomography of Retina
retinal imaging with low-cost OCT device - Device
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new OCT device to see if it takes images of the retina that are as good as a commercial device. Retinal imaging with a low-cost OCT device is used to treat Optical Coherence Tomography of the Retina. This form of retinal imaging has previously been approved by the FDA for a different condition. However, unlike in previous trials, none of the patients in this particular trial will receive a placebo.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: during study procedures (30 minutes)

during study procedures (30 minutes)
Contrast-to-Noise Ratio (CNR)
Number of Participants with Acceptable OCT Image Quality as Measured by Low-Cost OCT Device

Trial Safety

Trial Design

1 Treatment Group

OCT Imaging
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: retinal imaging with low-cost OCT device · No Placebo Group · N/A

OCT ImagingExperimental Group · 2 Interventions: retinal imaging with low-cost OCT device, retinal imaging with commercial OCT device · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during study procedures (30 minutes)
Closest Location: Duke University Medical Center · Durham, NC
Photo of Duke University Medical Center 1Photo of durham 2Photo of durham 3
2003First Recorded Clinical Trial
1 TrialsResearching Optical Coherence Tomography of Retina
1819 CompletedClinical Trials

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,137 Previous Clinical Trials
3,197,549 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,350 Previous Clinical Trials
3,324,539 Total Patients Enrolled
Adam Wax, Ph.D.Principal InvestigatorDuke University
5 Previous Clinical Trials
263 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.